Farar brings to BioSig over 30 years of experience in both public and private sectors. From 1999–2000, following presidential appointment and confirmation by the U.S. Senate, Farar served as the United States Representative to the 54th General Assembly at the United Nations. In February 2011, again following presidential appointment and confirmation by the U.S. Senate, Farar was named as a commissioner to the U.S. Advisory Commission on Public Diplomacy, which is charged with appraising U.S. government activities intended to understand, inform and influence foreign publics. The Commission reports to the President, the Secretary of State, and Congress. He currently serves as the chair of that Commission. From 2001 to 2005, he also served on the Board of Fire and Police Pension Commissioners of the City of Los Angeles.
In the private sector, Farar has served as CEO, board chairman, director, and consultant to a number of companies, including JDF Investment Co. LLC and IFC Financial Services Corp., and has served as an adviser to several other private and public companies.
“In addition to his commercial success, Sim brings very impressive achievements and deep understanding of public policy sector on regional, national and global levels. With his unique skills, innovative thinking and the strength of his relationships in our home town of Los Angeles, Sim is an invaluable addition to our Advisory Board,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies.
The goal of the newly formed Advisory Board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships and M&A. Current board members include California-based Kent Bennett Williams, CEO and Principal at Vista Asset Management LLC; and Texas-based Dr. Ramachandra Malya, a medical director and consulting nephrologist.
“As someone who followed BioSig’s efforts since the very beginning, I have always been impressed by the company’s progress and team’s dedication to address unmet clinical needs on a global scale. I’m pleased to join the team at this crucial time in the company’s life cycle and lend my support to further enhance BioSig’s performance,” said Farar.
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The company’s first product, the PURE EP System, is a cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward U.S. Food and Drug Administration 510(k) clearance for the PURE EP System.